Open AccessmiR‐423‐3p activates FAK signaling pathway to drive EMT process and tumor growth in lung adenocarcinoma through targeting CYBRD1
Author(s) -
Ma Jun,
Huang Wuhao,
Zhu Chaonan,
Sun Xiaoyan,
Zhang Qiang,
Zhang Lianmin,
Qi Qi,
Bai Xiaoming,
Feng Yun,
Wang Changli
Publication year - 2021
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.24044
Subject(s) - adenocarcinoma , cancer research , microrna , epithelial–mesenchymal transition , lung cancer , downregulation and upregulation , cell growth , focal adhesion , lung , biology , signal transduction , cancer , medicine , pathology , microbiology and biotechnology , gene , biochemistry
Background Lung adenocarcinoma (LUAD) is a malignant tumor with a high fatality rate and poor overall survival, while molecular targets diagnosing and alleviating lung cancer remain inadequate. Methods In this article, we highlighted the upregulation of microRNA‐423‐3p (miR‐423‐3p) in LUAD, especially in smokers aged over 40, and revealed that the high expression of miR‐423‐3p was significantly associated with smoker, age, and pathologic stage of LUAD patients. Results Moreover, overexpressing miR‐423‐3p could facilitate LUAD cell proliferation, invasion, adhesion, and epithelial–mesenchymal transition (EMT) process, while depleted miR‐423‐3p caused repressive influence upon it. Mechanically, we identified that miR‐423‐3p could activate FAK signaling pathway through binding to the 3'‐UTR of cytochrome B reductase 1 (CYBRD1). Furthermore, we demonstrated that CYBRD1 was lowly expressed in LUAD, and miR‐423‐3p overexpression could rescue the impairment of LUAD cell proliferation, invasion, adhesion, and EMT caused by CYBRD1 depletion. Noticeably, miR‐423‐3p depletion efficiently hindered LUAD tumor growth in vivo . Conclusion Collectively, our findings demonstrated that miR‐423‐3p/CYBRD1 axis could be regarded as a promising biomarker to alleviate the poor LUAD prognosis.